Kornimate/medical-research-clean huggingface dataset:
triage survey for neurology research eligibility

Conditions: Alzheimer Disease

Summary: triage-neuro is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored neurology clinical trials.

triage-neuro is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored neurology clinical trials. secondary objectives include identifying participant characteristics among the clinical trial-seeking population, identifying the percentage of potential participants currently taking prescribed memory medications that could exclude them from clinical trial participation, examining how changes in prescription memory medications impact performance on cognitive assessments, and identifying the percentage of potential participants whose laboratory results could exclude them from clinical trial participation.

Eligibility criteria:
inclusion criteria: * participant and study partner (when applicable) have signed an icf prior to study-specific procedures being performed. * participant and study partner (when applicable) are at least 18 years old. exclusion criteria: * participant lacks the language skills or cognitive ability to understand the screening process. * participant is pregnant, breast-feeding, or planning to become pregnant. * history of a clinically significant illness which in the investigator's opinion may impact participant safety or the ability to analyze study results. * participant represents an acute suicidal risk, as defined as a "yes" response to ideation on columbia-suicide severity rating scale questions 4 or 5, or answer "yes" to behavior questions within 90 days of screening. * moderate or severe substance use disorder within 90 days prior to screening, according to dsm-5 criteria that in the investigator's opinion could pose undue risk to the participant. * any condition that in the investigator's opinion makes a participant unsuitable for the study. * currently employed by adams clinical or a first-degree relative of an employee working on this study.
development of spin-lock and fse acquisitions based 3d quantitative biochemical imaging for osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: in hong kong, joint diseases are common health problems as identified by the elderly health service under the department of health. it accounts for most of the disability of the elderly in hong kong. in particular, osteoarthritis (oa) is on the rise and the prevalence of oa increases with age. women are more likely to have oa in knee and hip joints after menopause. a study in 2000 reported that among hong kong people aged 50 and above, 7 percent of men and 13 percent of women suffered from oa. with an ageing population, it is expected that oa will become a major public health problem in hong kong and worldwide and the socio-economic cost of supportive care to these patients can become a major burden to hong kong society and many regions in the world. early diagnosis and prevention of oa and effective technology for treatment monitoring are very important. at present, the management of oa is not optimal and standard quality indicators suggest that the majority of persons with the disease do not receive appropriate care. over half of the population affected with oa are unaware of the diagnosis. the research team have developed a quantitative and fully automated non-contrast mri application for early detection and monitoring of joint diseases. the whole project was funded by the innovation and technology fund (itf) (mrp/001/18x ) started in january 2019. this clinical trial is part of the quantitative assessment of this developed technology. the team anticipate this innovation will address both oa diagnosis, surveillance and management. this can potentially increase diagnostic capabilities with minimum efforts, improving patient awareness, and improved treatment monitoring of the disease state after the interventions. thus, the proposed technology is expected to provide betterment in the quality of life for the elderly population.


Eligibility criteria:
inclusion criteria: * all patients over the age of 18 * all patients must provide their written consent in the oa group * patients must be affected by primary osteoarthritis of the knee (according to acr - american college of rheumatology - classification) * all patients must have pain symptoms for more than or equal to 2 months * radiological evidence of osteoarthritis exclusion criteria: * contraindication to mri * patient with a mental disability * claustrophobia * inflammatory arthritis * ongoing pregnancy and breast-feeding * presence of severe diseases like terminal cancers * presence of metalwork in the knee * significant hematological diseases; * non-consenting patients who have not provided the written informed consent * gross lower limb deformity
determination of the efficacy and safety of psoralait versus placebo in the treatment of psoriasis

Conditions: Psoriasis

Summary: the purpose of this study is to determine the safety and efficacy of a new product, psoralait, as compared to a placebo in the treatment of psoriasis.


Eligibility criteria:
inclusion criteria: * patients who have been clinically diagnosed as suffering from psoriasis and are or aren't scheduled for narrow band ultraviolet b (uvb)phototherapy of affected areas,excluding face and genitalia. exclusion criteria: * women who are pregnant, lactating, planning to become pregnant, or women of child-bearing potential who have not successfully been using the same medically acceptable contraceptive methods over the previous 3 months, e.g., oral contraceptive agents, intrauterine device (iud) and barrier method plus spermicide. * use of topical anti psoriatic therapy (including topical retinoids, corticosteroids, or vitamin d analogs) on the areas to be treated within 2 weeks prior to the beginning of the study. * received systemic biologic therapy to treat psoriasis (for example: alefacept, etanercept, infliximab, adalimumab) within 12 weeks prior to the beginning of the study. * received systemic psoriasis therapy (for example: methotrexate, cyclosporine, systemic corticosteroids, retinoids such as acitretin) within 4 weeks prior to the beginning of the study. * received phototherapy (including laser), photo chemotherapy or climatotherapy within 4 weeks prior to the beginning of the study. * recent history (within past 12 months) of alcohol or substance abuse. alcohol abuse will be defined as \>14 drinks per week (1 drink = 12 oz beer, 4 oz wine, or 1.5 oz distilled spirits). * history of noncompliance to medical regimens or unwilling to comply with the study protocol. * participation in an investigational drug study within 30 days prior to the beginning of the study. * serious or unstable medical or psychological conditions that in the opinion of the investigator would compromise the subject's safety or successful participation in the study.

Keywords: psoriasis
clinical trial of pentoxifylline in patient with cirrhosis

Conditions: Cirrhosis; Liver Failure

Summary: in patients with cirrhosis and liver failure, pro-inflammatory cytokines (tnf alpha) might be responsible of severe complications and death. thus, the prevention of cytokine production should prevent complications and mortality. the aim of this study is to study the 2 months survival rate in patients with severe cirrhosis (child-pugh c) with pentoxifylline - an inhibitor of cytokine production. the 6 month mortality, the proportion of transplanted patients, the occurrence of complications (bacterial infection, renal failure, hepatic encephalopathy and gastrointestinal bleeding), plasma cytokine levels and fibrotest - a marker of fibrosis - will be also studied. this is a multicenter double blind randomized trial with a placebo. all adult patients with severe cirrhosis might be randomized after written consent. patients with severe carcinoma, intolerance or contraindication to pentoxifylline will not be included. patients receive either pentoxifylline or placebo 3 times a day for 6 months. three hundred and forty two patients are necessary to decrease mortality rate by 50% at 2 months in a beta risk of 10% and an alpha risk of 5%. patients will be seen every month.

the aim of this study is to study the 2 months survival rate in patients with severe cirrhosis (child-pugh c) with pentoxifylline - an inhibitor of cytokine production. the 6 month mortality, the proportion of transplanted patients, the occurrence of complications (bacterial infection, renal failure, hepatic encephalopathy and gastrointestinal bleeding), plasma cytokine levels and fibrotest - a marker of fibrosis - will be also studied. this is a multicenter double blind randomized trial with a placebo. all adult patients with severe cirrhosis might be randomized after written consent. patients with severe carcinoma, intolerance or contraindication to pentoxifylline will not be included. patients receive either pentoxifylline or placebo 3 times a day for 6 months. three hundred and forty two patients are necessary to decrease mortality rate by 50% at 2 months in a beta risk of 10% and an alpha risk of 5%. patients will be seen every month.

Eligibility criteria:
inclusion criteria: * adult patient of more than 18 years * child pugh c cirrhosis exclusion criteria: * pregnant woman * patient received anticoagulant * patient treated for arterial hypertension * patient with severe coronaropathy * patient with hyper sensibility of pentoxifylline * patient hospitalized for less 24 hours * patient admitted for a treatment of hepatocellular-carcinoma or collangio- carcinoma * patient with hiv * patient who has been transplanted * patient treated with immuno- suppressors * patient who has already received pentoxifylline for 3 months before inclusion * patient for whom the follow-up is considered impossible

Keywords: multicenter-randomized-trial pentoxifylline placebo cirrhosis liver failure cytokine
preventing suicide among sexual and gender diverse young adults in primary care in texas

Conditions: Suicide; Suicidal Ideation

Summary: the overall aim of this study is to reduce suicide among sexual and gender diverse youth ages 18-24 years old. this study will compare the effectiveness of two brief suicide prevention interventions that have been adapted for use with this population to use in primary care via telehealth and will recruit youth from primary care clinics in texas metropolitan areas. the primary study outcome is suicidal ideation. each clinic will be randomly assigned to deliver one of the two study interventions.


Eligibility criteria:
inclusion criteria: * be aged 18-24 at the time of enrollment * not have received mental health services in the past 90 days, excluding medication and case management * english-speaking * screen positive for suicide risk exclusion criteria: * are actively suicidal * have a developmental disability that would preclude them from participating in the study intervention * who are impaired due to psychosis, mania, or substance use that would prevent them from providing consent. * participants will also be excluded at yst-iii sites if they are unable to identify a minimum of one support person to participate in the intervention with them

Keywords: depression self-injurious behavior sexual and gender minority youth
ultrasound features of endometriosis of the uterosacral ligaments

Conditions: Endometriosis

Summary: ultrasound features most indicative of endometriosis of the uterosacral ligaments, which connect the cervix to the sacrum and are part of the uterus support structures, and verify the actual presence of endometriosis of these ligaments during surgery

it is estimated that 1 in 10 women of childbearing age is affected by endometriosis. objective examination alone is not sufficient to frame the pathology as the anatomic-clinical correspondence is relatively low: symptoms are not lesion specific and there may be asymptomatic women with pictures of severe endometriosis. accurate diagnosis of all endometriosis by transvaginal ultrasound at the preoperative stage is therefore essential to discriminate patients who need surgery from those who can benefit from medical therapy alone, but also to be able to select a surgeon with adequate experience for this type of surgery. in recent years, moreover, it has been highlighted that ureteral endometriosis is associated with ipsilateral lus injury. ureteral damage has a nuanced symptomatology and cases in which the patient manifests signs and symptoms suggestive of renal resentment are rare (flank pain, renal colic, hypertension). ureteral involvement can therefore lead to a silent loss of renal function, which in some cases requires nephrectomy. several studies have already shown that there is a correlation between ureteral endometriosis and uterosacral ligaments (lus) endometriosis, and that the likelihood of ureteral involvement increases with increasing nodule size. in light of this evidence and in order to improve the diagnostic power of the ultrasound method, it is therefore important to find the best combination of ultrasound parameters to predict endometriosis in lus with sufficient accuracy.

Eligibility criteria:
inclusion criteria: * women with a clinical and/or ultrasound diagnosis of endometriosis who are candidates for surgery; * age between 18 and 50 years; * signature of informed consent to the study exclusion criteria: * post-menopausal women (spontaneous or iatrogenic); * virgo patients; * hysterectomised patients; * pregnant patients; * patients undergoing pelvic/vaginal radiotherapy; * previous lus surgery; * clinical diagnosis of pelvic organ prolapse; * preoperative ultrasound more than 60 days prior to surgery; * failure at surgery and any subsequent histopathological examination to find pelvic endometriosis

Keywords: endometriosis gynaecology surgery uterus sacral ligaments
efficacy study of stenting, paclitaxel eluting balloon or atherectomy to treat peripheral artery disease

Conditions: Peripheral Vascular Diseases

Summary: the purpose of the study is to evaluate the efficacy of stenting after dilation with or without paclitaxel-eluting balloon or atherectomy in patients with symptomatic peripheral artery disease.

the superficial femoral artery is a common place for arteriosclerosis in patients symptomatic for lower extremity vascular disease. advances in percutaneous transluminal angioplasty (pta) and stenting have provided new options for the treatment of the disease in this arterial segment. despite the initial technical success rate of more than 95% the late clinical failure remains an important concern. restenosis after pta occurs in 40-60% within one year. percutaneous removal of the obstructive material through atherectomy may reduce restenosis rate. so far, data in support of excisional atherectomy derive from registries. another attempt to reduce restenosis is the use of paclitaxel eluting balloons (peb). first clinical studies suggest that the use of pebs during percutaneous treatment of femoropopliteal disease is associated with significant reductions in late lumen loss and target-lesion revascularization. there is no randomized comparison of this three different interventional strategies. thus the aim of this study is to evaluate the efficacy of these strategies in terms or reduction of diameter stenosis at follow-up angiogram.

Eligibility criteria:
inclusion criteria: * symptomatic ≥ 70% stenosis of the sfa (rutherford stage 2-6) * written informed consent exclusion criteria: * acute ischemia and/or acute thrombosis of the sfa * untreated ipsilateral iliac artery stenosis \>70% * previous stenting of the sfa * popliteal stenosis \>70% * severe renal insufficiency

Keywords: stent atherectomy paclitaxel-eluting balloon
assessment of macrophage activation syndrome in still's disease

Conditions: Macrophage Activation Syndrome; Still's Disease, Adult-Onset; Stills Disease, Juvenile-Onset

Summary: assessment of macrophage activation syndrome in still's disease: retrospective chart analysis of patient history, symptom resolution and treatment characteristics

this is an observational, retrospective cohort study on the treatment utilization and outcomes of macrophage activation syndrome (mas) refractory to glucocorticoids (gc) in patients with still's disease. the study will be conducted entirely through medical chart abstraction; all data will be taken from the patient's medical record, with no additional assessments.

Eligibility criteria:
inclusion criteria: * age \>6 months and ≤80 years at the beginning of the index mas episode. * diagnosis of still's disease (sjia (systemic juvenile idiopathic arthritis) or aosd (adult onset stills disease) diagnosis). * diagnosis of mas according to treating physician in the medical record. * patients who have received at least 3 consecutive days of gc after diagnosis of mas and/or are judged by the investigator to be refractory to gc due to clinical worsening of patient's condition . * the onset of the index mas episode occurred between 01 january 2012 and 30 september 2022. exclusion criteria: * a diagnosis of primary hemophagocytic lymphohistiocytosis (hlh) prior to the beginning of the index mas episode. * confirmed malignancy prior to the beginning of the index mas episode. * patient treated with any investigational product as a part of clinical trial during the index mas episode.
telephone contact between hospital and general practitioner about medication review for older patients

Conditions: Older Patients; Medication Review; Cross-sectional Communication

Summary: in this trial, the feasibility of cooperation between clinical pharmacists and physicians by conducting a telephone follow-up conversation between the hospital geriatrician, the general practitioner and the clinical pharmacist is evaluated. during hospital stay the clinical pharmacist and the geriatrician will review older patients' medication and discuss the future treatment with the general practitioner after discharge by telephone or medico-technology. the first part of the feasibility study will be a qualitative baseline measure of characteristics of the participants and work flow. the second part will be a pilot randomized controlled study where participants will be allocated to either usual care or medication review and follow up contact


Eligibility criteria:
inclusion criteria: \* 5 drugs or more exclusion criteria: * terminal illness * not able to speak and understand danish
effects of mrsa bactericidal gel to promote healing and eliminate mrsa in cssti vancogel(tm)

Conditions: Bacterial Infections; Wounds

Summary: based on personal experience and the literature it is reasonable expectation that vancomycin is a viable treatment in a direct contact form to eliminate mrsa from open wounds in order to heal the wounds by conventional means. the key question in my research has been to measure the effectiveness of my vancomycin gel by culturing the wound, applying the gel in a controlled manner and then culturing the wound after one week. the end point to achieve in the process, is a clinical response of accelerated healing and negative culture report. another question to solve is the duration of potency and stability of the vancomycin gel over time.

over a prior preliminary 33 month study i have found negative cultures at the end of one week of treatment and have had microbiological studies establishing the same mic zones in culture media greater than 15mm over a 33 month time frame. the microbiological and hplc studies are completed at present and approved. i have started the phase 2 studies on august 1,2011 as authorized by the fda on june 22,2011.

Eligibility criteria:
inclusion criteria: * mrsa infected open wounds * acute and chronic wounds * type of wounds: venous stasis,diabetic, pressure, post surgical, post traumatic, and spontaneous * infection criteria: include a positive culture for mrsa * location of ulcers: any place on the body * diagnosis of mrsa: based on tissue cultures of mrsa * willing and reliable patients * study to include only one ulceration no more than 50 square centimeters * the study to include stages two and three ulcerations exclusion criteria: * non-compliant patients * patient must accept all issues in consent form * non compliance to include failed appointments * wounds greater than 50sq. cm * no wounds deeper than soft tissue * ischemic or vascular disease, dermatitis, immune deficiency,or psoriasis * allergy to vancomycin * post irradiation ulceration * bleeding disorders * skin allergies to adhesives and tape * ulcers related to cancers * multiple wounds * stage 4 ulcerations * patients in any other trial * patients with any other conditions which, in the opinion of the investigator/doctor, would preclude participation in the study.

Keywords: elimination of mrsa in open wounds mrsa infected open wounds
an open-label study of the safety and efficacy of subcutaneous recombinant interferon-gamma 1b (ifn-gamma 1b) in patients with idiopathic pulmonary fibrosis (ipf)

Conditions: Lung Disease; Pulmonary Fibrosis

Summary: study gipf-004 is an open-label, multicenter study that will enroll approximately 250 patients who complete protocol gipf-001. the purpose of this study is to assess the safety and efficacy of continued ifn-gamma 1b therapy in this well-defined cohort of patients for up to 48 weeks.


Eligibility criteria:
male or female idiopathic pulmonary fibrosis 20-79 years must have participated in the intermune protocol gipf-001 study.

Keywords: idiopathic pulmonary fibrosis ipf
desflurane and anesthesia recovery period in endonasal endoscopic pituitary adenoma resection

Conditions: Pituitary Neoplasms

Summary: nasal packing is required after endoscopic pituitary adenoma resection. the patient can only breathe through the mouth. the blood and secretion in the nasal cavity may be inhaled into the trachea after the operation. gh-secreting pituitary adenoma causes pharyngeal soft tissue and tongue hypertrophy. these conditions increase the risk of respiratory obstruction and hypoxemia during anesthesia recovery. propofol total intravenous anesthesia has a rapid effect and a low incidence of nausea and vomiting. patients anesthetized with desflurane recover quickly is conducive to early recovery of respiratory function and orientation. this study intends to compare the effects of desflurane and propofol on the quality of anesthesia recovery period in patients undergoing endonasal endoscopic pituitary adenoma resection and to provide clinical evidence for the use of desflurane in neurosurgical anesthesia.


Eligibility criteria:
inclusion criteria: * 18-65 years; * elective endoscopic transsphenoidal resection of pituitary adenomas; * asa status i-iii; * informed consent signed by patients. exclusion criteria: * emergency surgery; * complicated with cerebrovascular disease; * complicated with pulmonary disease, oxygen saturation below 95% without oxygen; * expected to retain endotracheal intubation; * preoperative disturbance of consciousness was not compatible with assessment; * complicated with primary hypothyroidism; * previous history of cervical surgery, burns, and radiotherapy; * bmi \>30kg/m2; * invasive pituitary adenoma with knosp grade 4.